Literature DB >> 9518148

Specific gas chromatographic analysis of diethylcarbamazine in human plasma using solid-phase extraction.

S Lee1, D A Casteel, L Fleckenstein.   

Abstract

Diethylcarbamazine (DEC, 1-diethylcarbamyl-4-methylpiperazine) is an antiparasitic piperazine derivative used in the treatment of lymphatic filariasis. DEC-N-oxide is a major metabolite in humans which has antifilarial activity. Gas chromatographic analysis of DEC in plasma can be complicated by the presence of the metabolite, since the thermally unstable DEC-N-oxide is converted to a material which coelutes with DEC under the conditions of the analysis. We now report a method to separate DEC-N-oxide from DEC in plasma using solid-phase extraction with subsequent gas chromatographic analysis using a nitrogen specific detector. 1-Diethylcarbamyl-4-ethylpiperazine (E-DEC) was the internal standard. The standard curve of DEC is linear in the range of 10 to 200 ng/ml. The limit of detection is 4 ng/ml. Reproducibility at 10, 100 and 200 ng/ml concentration points of the standard curve gives coefficients of variation of 6.1%, 7.8% and 1.6%, respectively. Recovery following solid-phase extraction is 99.3% for DEC and 94.8% for the internal standard. This sensitive and specific analytical method is suitable for pharmacokinetic studies of DEC.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9518148     DOI: 10.1016/s0378-4347(97)00424-6

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  2 in total

Review 1.  Control of nematode parasites with agents acting on neuro-musculature systems: lessons for neuropeptide ligand discovery.

Authors:  Richard J Martin; Alan P Robertson
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

2.  LC-MS/MS method for simultaneous determination of diethylcarbamazine, albendazole and albendazole metabolites in human plasma: Application to a clinical pharmacokinetic study.

Authors:  Yashpal S Chhonker; Constant Edi; Daryl J Murry
Journal:  J Pharm Biomed Anal       Date:  2017-12-24       Impact factor: 3.935

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.